OcuMension Therapeutics lists on HKEx
Ophthalmic therapy provider OcuMension Therapeutics goes public in Hong Kong. Eight Roads Ventures China invested in its Series B round.

Opthalmic therapy provider OcuMension Therapeutics offered 105.93 million shares at a price of HK$14.66, raising HK$1.55 billion. The stock rose as much as 193 per cent to HK$43 in early trading.

It was oversubscribed 1,895.76 times. The funds will mainly be used to develop its new drugs as well as its core product OT-401, which treats chronic eye inflammation affecting the posterior segment of the eye.

Share

The information on these pages is intended solely for the benefit of entrepreneurs and businesses seeking venture capital investment. Eight Roads does not offer and is not offering to provide investment advisory services nor is it offering to engage in any transactions in securities.